- Our Focus
Reimagining medicine to transform cancer
At Novartis, we focus on five key cancer areas where we have identified patient needs and promise within our portfolio – breast cancer, lung cancer, melanoma, kidney cancer and hematology.
From Cancer to Cures
Our new monthly series "Let's Talk About the C Word: From Cancer to Cures" featuring President of Novartis Oncology Dr. Susanne Schaffert, addresses challenging cancer related topics.
Reimagining cancer in the workplace
Novartis is strongly committed in helping and supporting employees impacted by cancer through the global workplace program Ensemble – Caring for Colleagues.
Learn about AI in cancer research
Artificial intelligence decodes cancer pathology images
For more than 25 years, we have been at the forefront of driving scientific advancements and improving clinical practice in collaboration with the global breast cancer community. With one of the most diverse breast cancer pipelines and the largest number of compounds in development, Novartis leads the industry in discovery of new therapies and combinations.
Over the past decade, our research has supported the evolution of treatment approaches for patients living with mutation-driven types of lung cancer. We remain focused on the global lung cancer community through ongoing studies as well as the exploration of investigational compounds that target genomic biomarkers.
Melanoma is the most serious type of skin cancer, and in many cases is caused by damage to the DNA in skin cells; more than half of melanoma cases are caused by these genetic changes. Through research, investigational studies and advocacy, Novartis brings attention and support to those battling advanced melanoma.
Novartis has a strong heritage in the research, development and discovery of treatments for advanced renal cell carcinoma (RCC). RCC is the most common type of kidney cancer, accounting for 90% of all kidney tumors.
We are passionate about our work for patients with life-threatening blood cancers and serious non-cancer blood disorders. Together with the medical community, we are reimagining hematology.